The results indicated that BC patients expressing higher levels of KMT1A had a shorter mean survival time than did the patients expressing lower levels of KMT1A in both GSE13507 (P = 0.0086) and GSE32894 (P = 0.0449) cohorts (Figure 1J). Here, SUV39H1 is linked to breast cancer.